Skip to NavigationSkip to content

heart disease

Insider Interview: Reducing the risk of adverse cardiovascular events

Published on 03/02/20 at 12:35pm

Rodrigo Gribble, Vice President Cardiovascular at AstraZeneca, breaks down recently published data from the PEGASUS trial of ticagrelor, a potential new treatment for patients with coronary artery disease, and how this may benefit patients who have suffered from previous heart attacks.

Recent published data in the European Heart Journal – Cardiovascular Pharmacotherapy show efficacy and safety in a large study with antithrombotic therapy ticagrelor, with a significant reduction in the risk of major adverse cardiovascular events.

AstraZeneca to discontinue trial for heart disease drug Epanova

AstraZeneca expects a $100 million writedown for its heart disease drug Epanova, as it discontinues its late stage trial.

This trial was examining Epanova’s benefit to patients when mixed with dyslipidaemia. The Phase 3 STRENGTH trial was recommended to close by the Data Monitoring Committee.

STRENGTH is a large, global CV outcomes trial designed to evaluate the safety and efficacy of Epanova compared to placebo.

FDA approves alternative approach for Abbot HeartMate 3 heart pump

The FDA announced today that it has approved a new alternative surgical technique for Abbot’s HeartMate 3 heart pump.

The less invasive approach is designed to provide surgeons with a choice in the surgical method it uses to install this pump. This is to allow patients to avoid open-heart surgery.

AstraZeneca and Novoheart team up to develop human ‘heart-in-a-jar’

AstraZeneca and Novoheart are collaborating on developing a functioning miniature human heart model of heart failure, a first of its kind.

The ‘heart-in-a-jar’, Novoheart’s proprietary 3D human ventricular cardiac organoid chamber (hvCOC) technology, will be made from human stem cells and will replicate the key characteristics of heart failure. This will include preserved ejection fraction (HFpEF), a common condition especially in women and the elderly.

Heart disease deaths increase for first time in 50 years

Image Credit: Bryan Brandenburg

Deaths from heart disease among people under the age of 75 have increased for the first time in 50 years.

Figures show an increase in the number of deaths since 2014, with the total number of heart disease deaths increasing from 41,042 in 2014 to 42,384 in 2017.

Meanwhile the number of deaths caused by heart and circulatory diseases in under-65s increased from 17,982 in 2012 to 18,668 in 2017.

Galectin-3: The protein paving new treatment avenues

Published on 01/11/18 at 11:14am

Matthew Blakeley, LADI-III Beamline Scientist at Institut Laue-Langevin (ILL) and Derek Logan, Associate Professor in Structural Biology at Lund University, discuss galectin-3 and its link to diabetes, heart disease and breast cancer, and how it could lead us to new therapies.

Can you provide a bit of background on galectins and why our understanding of them is important in the discovery/design of new treatments?

"Triple pill" blood pressure combo proves more effective, safe than standard care

A “triple pill” combining three established and effective drugs at low dosage levels could prove much more effective in treating high blood pressure than any of its constituent elements alone, according to research conducted by the George Institute for Global Health, an independent medical institution with branches in the UK, Australia, and India.

“It's estimated more than a billion people globally suffer from high blood pressure, with the vast majority having poorly controlled blood pressure,” said lead study author Dr Ruth Webster, Head of Research Programs at the George Institute

EMA issues global recall of heart drugs over cancer risk contamination

Several drugs designed for the treatment of high blood pressure and heart conditions have been recalled across Europe over fears they could contain a probable carcinogen and thus pose an increased risk of cancer in users, it has emerged.

New AI system for lung cancer and heart disease could save NHS billions

A team of researchers at Oxford’s John Radcliffe Hospital have unveiled a new artificial intelligence system which they claim could cut operational costs by billions of pounds at NHS hospitals by helping to detect heart disease and lung cancer early, even suggesting the health service could benefit from the platform for free by as early as the summer.

Novartis targets specific patient population with strong Ilaris Phase 3 data

Novartis has presented new Phase 3 data on its cardiovascular drug Ilaris (canakinumab) which demonstrate particular efficacy in a specific subgroup of the trial’s patient population – a subgroup which the Swiss drugmaker is now looking to target with the drug.

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches